Experimental knee shot aims to slow arthritis damage
NCT ID NCT03706521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small, early-phase study tested a single injection of lorecivivint into the knee joint of 13 people with moderate-to-severe knee osteoarthritis. The goal was to see if the drug could slow cartilage loss, measured by MRI scans. The trial was terminated early, so the results are limited and not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lorecivivint (a drug injected into the knee joint)
What this could lead to
If it works, this could point toward a treatment that slows cartilage loss in knee osteoarthritis.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited and may not apply to a larger population. The drug may not prove effective or safe in the long run.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
San Francisco, California, 94158, United States